T Therapeutics Closes Series B for TCR Bispecific Programs

Company T-Therapeutics Event Type Series B financing ($133 million) Modality TCR-CD3 bispecific T-cell engagers Asset Two undisclosed lead programs Target Peptide-HLA complexes; CD3 Disease Area Oncology; autoimmune disease Summary T-Therapeutics announced a $133 million Series B on November 5 to take TCR-CD3 bispecific programs in…